-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BOc2T0att/sAll7Kivydt8dAcZMuwwVWgggEUSB2I8QYWQJ8lkO+yAJRg7bFrB8G pJOQ7D4nx4wkNn4MMC/vfA== 0000891020-06-000411.txt : 20061215 0000891020-06-000411.hdr.sgml : 20061215 20061215161505 ACCESSION NUMBER: 0000891020-06-000411 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061212 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20061215 DATE AS OF CHANGE: 20061215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 061280622 BUSINESS ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 v25885e8vk.htm FORM 8-K e8vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 12, 2006
 
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
 
         
DELAWARE
(State or other jurisdiction
of incorporation or organization) 		  033-20897-D
(Commission
File Number) 		  91-2099117
(IRS Employer
Identification No.)
22118 20th Avenue SE, Suite 204
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement.
SIGNATURES

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement.
     On December 12, 2006, Helix BioMedix, Inc. (the “Company”) entered into a Non-Exclusive License Agreement (the “License Agreement”) with Grant Industries, Inc. (“GI”). Pursuant to the License Agreement, the Company granted to GI a non-exclusive license under certain Company patents and related technology to formulate certain proprietary Company peptides into premix products, and to market and sell those premix products for use in final products in the cosmetic and over-the-counter personal care market. The License Agreement includes certain sublicense rights. The initial term of the License Agreement is three years. In consideration for the license, GI agreed to pay royalties to the Company on its sales of premix products as set forth in the License Agreement.
SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  HELIX BIOMEDIX, INC.
 		  
Dated: December 15, 2006  By:   /s/ David H. Kirske   
    David H. Kirske   
    Vice President and Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----